Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies.

摘要: Objectives To assess the role of resistance mutations in subjects experiencing virological failure on zidovudine (ZDV) and lamivudine (3TC) combined with a protease inhibitor (PI) to those failing ZDV/3TC alone. Design methods Samples were obtained from previously antiretroviral therapy-naive enrolled into two studies, AVANTI 2 3. Subjects randomized receive either: or plus indinavir (IDV) for 52 weeks (AVANTI 2), nelfinavir (NFV) 28 3). Emergence viral was monitored by population sequencing phenotypic determined recombinant virus assay. Results Genotypic data plasma HIV-1 RNA > 400 copies/ml. In 2, ZDV detected 27% ZDV/3TC-treated patients at week 52, but absent treated ZDV/3TC/IDV. No either arm 3 developed 28. The M184V mutation most both studies. presence was, however, associated significantly lower RNA levels when compared values before initiation treatment. There high frequency (4 11) L10F substitution ZDV/3TC/IDV-treated that did not result any PIs tested. Conclusions ZDV/3TC/PI-treated they slowly ZDV/3TC. Few known confer PI ZDV/3TC/PI arms study. low prevalence is encouraging regarding future treatment options these patients.